KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Current Deferred Revenue (2016 - 2023)

Jazz Pharmaceuticals has reported Current Deferred Revenue over the past 14 years, most recently at $4000.0 for Q3 2023.

  • Quarterly results put Current Deferred Revenue at $4000.0 for Q3 2023, down 99.54% from a year ago — trailing twelve months through Sep 2023 was $4000.0 (down 99.54% YoY), and the annual figure for FY2022 was $463000.0, down 81.89%.
  • Current Deferred Revenue for Q3 2023 was $4000.0 at Jazz Pharmaceuticals, roughly flat from $4000.0 in the prior quarter.
  • Over the last five years, Current Deferred Revenue for JAZZ hit a ceiling of $10.8 million in Q3 2019 and a floor of $4000.0 in Q1 2023.
  • Median Current Deferred Revenue over the past 5 years was $2.6 million (2021), compared with a mean of $3.0 million.
  • Biggest five-year swings in Current Deferred Revenue: skyrocketed 81.31% in 2019 and later crashed 99.76% in 2023.
  • Jazz Pharmaceuticals' Current Deferred Revenue stood at $4.7 million in 2019, then grew by 2.99% to $4.9 million in 2020, then plummeted by 47.42% to $2.6 million in 2021, then tumbled by 81.89% to $463000.0 in 2022, then plummeted by 99.14% to $4000.0 in 2023.
  • The last three reported values for Current Deferred Revenue were $4000.0 (Q3 2023), $4000.0 (Q2 2023), and $4000.0 (Q1 2023) per Business Quant data.